Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma

Research output: Contribution to journalArticle

Standard

Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. / Morris, Mark; Ricketts, Christopher; Gentle, Dean; Abdulrahman, M; Clarke, N; Brown, M; Kishida, T; Yao, M; Latif, Farida; Maher, Eamonn.

In: Oncogene, Vol. 29, No. 14, 01.04.2010, p. 2104-2117.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Morris, Mark ; Ricketts, Christopher ; Gentle, Dean ; Abdulrahman, M ; Clarke, N ; Brown, M ; Kishida, T ; Yao, M ; Latif, Farida ; Maher, Eamonn. / Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. In: Oncogene. 2010 ; Vol. 29, No. 14. pp. 2104-2117.

Bibtex

@article{4022a0d9a1ce4b29b16daf9bb5c83759,
title = "Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma",
abstract = "Promoter region hyermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many types of human cancers. Functional epigenetic studies, in which gene expression is induced by treatment with demethylating agents, may identify novel genes with tumour-specific methylation. We used high-density gene expression microarrays in a functional epigenetic study of 11 renal cell carcinoma (RCC) cell lines. Twenty-eight genes were then selected for analysis of promoter methylation status in cell lines and primary RCC. Eight genes (BNC1, PDLIM4, RPRM, CST6, SFRP1, GREM1, COL14A1 and COL15A1) showed frequent (>30% of RCC tested) tumour-specific promoter region methylation. Hypermethylation was associated with transcriptional silencing. Re-expression of BNC1, CST6, RPRM and SFRP1 suppressed the growth of RCC cell lines and RNA interference knock-down of BNC1, SFRP1 and COL14A1 increased the growth of RCC cell lines. Methylation of BNC1 or COL14A1 was associated with a poorer prognosis independent of tumour size, stage or grade. The identification of these epigenetically inactivated candidate RCC TSGs can provide insights into renal tumourigenesis and a basis for developing novel therapies and biomarkers for prognosis and detection. Oncogene (2010) 29, 2104-2117; doi: 10.1038/onc.2009.493; published online 15 February 2010",
keywords = "methylation, renal cell carcinoma, epigenetics",
author = "Mark Morris and Christopher Ricketts and Dean Gentle and M Abdulrahman and N Clarke and M Brown and T Kishida and M Yao and Farida Latif and Eamonn Maher",
year = "2010",
month = apr,
day = "1",
doi = "10.1038/onc.2009.493",
language = "English",
volume = "29",
pages = "2104--2117",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "14",

}

RIS

TY - JOUR

T1 - Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma

AU - Morris, Mark

AU - Ricketts, Christopher

AU - Gentle, Dean

AU - Abdulrahman, M

AU - Clarke, N

AU - Brown, M

AU - Kishida, T

AU - Yao, M

AU - Latif, Farida

AU - Maher, Eamonn

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Promoter region hyermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many types of human cancers. Functional epigenetic studies, in which gene expression is induced by treatment with demethylating agents, may identify novel genes with tumour-specific methylation. We used high-density gene expression microarrays in a functional epigenetic study of 11 renal cell carcinoma (RCC) cell lines. Twenty-eight genes were then selected for analysis of promoter methylation status in cell lines and primary RCC. Eight genes (BNC1, PDLIM4, RPRM, CST6, SFRP1, GREM1, COL14A1 and COL15A1) showed frequent (>30% of RCC tested) tumour-specific promoter region methylation. Hypermethylation was associated with transcriptional silencing. Re-expression of BNC1, CST6, RPRM and SFRP1 suppressed the growth of RCC cell lines and RNA interference knock-down of BNC1, SFRP1 and COL14A1 increased the growth of RCC cell lines. Methylation of BNC1 or COL14A1 was associated with a poorer prognosis independent of tumour size, stage or grade. The identification of these epigenetically inactivated candidate RCC TSGs can provide insights into renal tumourigenesis and a basis for developing novel therapies and biomarkers for prognosis and detection. Oncogene (2010) 29, 2104-2117; doi: 10.1038/onc.2009.493; published online 15 February 2010

AB - Promoter region hyermethylation and transcriptional silencing is a frequent cause of tumour suppressor gene (TSG) inactivation in many types of human cancers. Functional epigenetic studies, in which gene expression is induced by treatment with demethylating agents, may identify novel genes with tumour-specific methylation. We used high-density gene expression microarrays in a functional epigenetic study of 11 renal cell carcinoma (RCC) cell lines. Twenty-eight genes were then selected for analysis of promoter methylation status in cell lines and primary RCC. Eight genes (BNC1, PDLIM4, RPRM, CST6, SFRP1, GREM1, COL14A1 and COL15A1) showed frequent (>30% of RCC tested) tumour-specific promoter region methylation. Hypermethylation was associated with transcriptional silencing. Re-expression of BNC1, CST6, RPRM and SFRP1 suppressed the growth of RCC cell lines and RNA interference knock-down of BNC1, SFRP1 and COL14A1 increased the growth of RCC cell lines. Methylation of BNC1 or COL14A1 was associated with a poorer prognosis independent of tumour size, stage or grade. The identification of these epigenetically inactivated candidate RCC TSGs can provide insights into renal tumourigenesis and a basis for developing novel therapies and biomarkers for prognosis and detection. Oncogene (2010) 29, 2104-2117; doi: 10.1038/onc.2009.493; published online 15 February 2010

KW - methylation

KW - renal cell carcinoma

KW - epigenetics

U2 - 10.1038/onc.2009.493

DO - 10.1038/onc.2009.493

M3 - Article

C2 - 20154727

VL - 29

SP - 2104

EP - 2117

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 14

ER -